Clinical trial · Observational
Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Kazakh Nationality
Preventive and Personalized Medicine (2021-2023)
NCT05095155CI-TRIAL-00064679completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To search for a genetic marker of B-cell leukemias and lymphomas in children of Kazakh nationality, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with B-cell leukemias and lymphomas in children of Kazakh nationality and normal control will be performed.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| B Cell Leukemia | Chronic Lymphocytic Leukemia | ALIAS | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SNP analysis of the DNA | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Experimental group:
- description
- children with B-cell leukemia and lymphoma of Kazakhstani nationality
- interventionNames
- Genetic: SNP analysis of the DNA
- label
- Control group
- description
- children without B-cell leukemia and lymphoma of Kazakhstani nationality
- interventionNames
- Genetic: SNP analysis of the DNA
Primary outcomes (1)
- measure
- Associated with B-cell lymphoma and B-cell acute lymphoblastic leukemia
- timeFrame
- 1 year
- description
- Genotype frequency of SNP in the study genes of participants and control participants.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ethnicity - Kazakhs in at least three generations * active disease or a history of B-line ALL or B-NHL, established on the basis of morphological, cytochemical, immunophenotypic or immunohistochemical research methods with confirmation of the fact of the disease in medical documentation * Signed voluntary informed consent of the legal representative to participate in the project Exclusion Criteria: * Children suffering from other types of malignant neoplasms * Children with B-linear leukemia and lymphomas with concomitant specified genetic and chromosomal diseases * Children of non-Kazakh nationality * Absence of signed informed consent or informed refusal of the legal representative to participate in the study before starting therapy
References
Publications (0)
Data not yet available
No reference posted for this study.